Laboratory Investigation of Cardiac Ischemia
Overview
This study guide explores the laboratory investigation of cardiac ischemia, detailing the types of cardiovascular ischemia, biomarkers for diagnosis, and diagnostic criteria following various myocardial injuries.
Page 1: Introduction
Laboratory Investigation of Cardiac Ischemia by Karel Kotaska.
Page 2: Types of Cardiovascular Ischemia
Ischemia: The restriction of blood flow to tissues, causing a shortage of oxygen needed for cellular metabolism. Types of ischemia:
Dilated Ischemia
Hypertrophic Stress-Related Ischemia
Myocardial Infarction: Blockage of blood flow leading to heart tissue death.
Heart Failure: A chronic condition where the heart does not pump blood efficiently.
Cardiomyopathies: Diseases affecting the heart muscle.
Pulmonary Embolism: A blockage in a pulmonary artery.
Cardiac Injury:
Indicators of cardiac injury include the elevation of biomarkers.
Wall Stress: Factors that contribute to cardiac injury include trauma, mechanical factors, viral infections (myocarditis), bacterial toxins, and sepsis-related myocardial depression.
Page 3: Blood Flow in Ischemic Conditions
Normal Artery: Shows normal blood flow.
Atherosclerotic Artery: Exhibits abnormal blood flow due to plaque and narrowed lumen, leading to potential ischemic conditions.
Page 4: Biomarkers in Cardiac Ischemia
Key biomarkers include LDL, oxLDL, CRP, Il-6, Il-10, Il-18, TNF, MMP-9, MPO, VCAM, ICAM, sCD40L, PIGF, PAPP-A, IMA, VMK, Cholin, BNP, HFABP, Urokortin, ADMA, cTnI, cTnT, Myoglobin, GPBB, CAIII, MLC-1, BNP, NT-proBNP.
Clinical Significance:
Plaque: Unstable plaque can lead to rupture and thrombosis, resulting in ischemia, necrosis, and cardiac remodeling.
Page 5: Characteristics of Ideal Biomarkers
High Sensitivity: Ability to detect the disease even in low quantities.
High Specificity: Accuracy in identifying only the target disease.
Rapid Release: Essential for early diagnosis, helping to initiate treatment quickly.
Long Half-Life: Beneficial for diagnosing late-stage diseases.
Cost-Effectiveness: Ensuring tests are practical for wide use.
Short Turnaround Time (TAT): Needed for timely intervention.
Precision and Accuracy: Critical for influencing treatment pathways and improving patient outcomes.
Prognostic Factor: The ability to predict disease outcomes based on test results.
Page 6: Laboratory Markers of Myocardial Necrosis
Factors Affecting Diagnostic Efficiency:
Size of Biomarker Release: Smaller proteins are released easier and faster than larger molecules.
Cellular Localization:
Membrane proteins are released prior to cytosolic proteins.
Contractile proteins are different based on solubility and release rates.
Specificity: Troponin (cTn) is specific for cardiomyocytes.
Clearance Mechanisms: Influence how long biomarkers remain detectable.
Page 7: Diagnostic Criteria for Ischemia
WHO/ACCF/AHA/ESC Criteria for Acute Ischemic Myocardial Infarction (AIM):
Chest pain lasting more than 20 minutes.
ECG changes indicative of injury or ischemia.
Elevation of cardiac biomarkers.
A single cTnI value above the 99th percentile of the Upper Reference Limit (URL).
Correlation: Elevation of cardiac biomarkers correlates closely with necrosis of heart tissue.
Page 8: Myoglobin as a Biomarker
Elevation Timeline: Myoglobin levels rise 2 hours after ischemic onset, peaking at 6-9 hours, and return to reference levels after about 36 hours.
False Positives: May occur due to muscle injuries or factors such as manual resuscitation or impaired renal function.
Negative Predictive Value:
Shows 60% NPV at 3 hours after ischemia and 90% NPV at 4 hours, helping to exclude acute coronary lesions.
Page 9: Creatinine Kinase and Isoenzymes
Creatinine Kinase (CK):
Elevates 4-6 hours after ischemia onset but is not specific for cardiac injury.
Influenced by ethnicity, gender, and musculature.
CK Isoenzyme - MB:
Cardiospecific, showing enzymatic activity or mass concentration.
Elevation indicates amount of necrotic tissue, with normalization after 5 days.
Helps detect reinfarction in the early stages post-AIM.
Page 10: CK and CK-MB Levels in Different Patients
Observations classified by different scenarios of acute myocardial infarction (AIM).
Examples include AIM without complications, normal CK-MB values after intramuscular injection affecting CK levels, reinfarction cases, and two infarcts followed by variable CK and CK-MB responses.
Current Preference: High-sensitivity cardiac troponin I (hs-cTnI) is preferred over CK-MB in diagnostics for its specificity and sensitivity.
Page 11: Cardiac Troponins
Troponin Structure:
Troponin C: Binds calcium ions.
Troponin I: Functions as a calcium-dependent inhibitor affecting myofilament interaction.
Troponin T: Connects troponins C and I to tropomyosin.
Role of Troponin Complex: Together, these proteins control muscle contraction and relaxation in striated muscle cells.
Page 12: hs-cTnI vs. cTnI
hs-cTnI and cTnI differ in units and cutoff values:
hs-cTnI measured in ng/L with gender-specific cutoff values; males: 156 ng/L, females: 342 ng/L.
cTnI measured in µg/L with a general cutoff of 0.300 µg/L.
Coefficient of Variation (CV): hs-cTnI has a CV < 10%, while cTnI has CV < 20%.
Page 13: Diagnostic Power of cTn
Evaluating Sensitivity, Negative Predictive Value (NPV), Specificity, and Positive Predictive Value (PPV) of cTnI and cTnT.
cTnI: Sensitivity 95%, NPV 61%, specificity 34%, PPV 85%.
cTnT: Sensitivity 78%, NPV 83%, specificity 71%, PPV 65%.
Cutoff Value: As specified at the 99th percentile.
Page 14: Changes in cTn During Testing
Troponin analyses categorize results from very early to very late sampling schedules concerning acute myocardial infarction and chronic injury patterns based on observed delta values in patient populations.
Page 15: Cardiac Troponins in Disease Staging
Differential references in cTn status during acute myocardial infarction versus chronic myocardial injury tied to symptom onset timeline.
Interpretation of delta values as demonstrated in diagnostic frameworks to imply risk stratification strategies for heart disease management.
Page 16: cTn Correlation with Infarct Size
Statistical significance represented by linear correlation between cTn elevation and size of myocardial infarction, showing a strong relationship quantified by R² = 0.829 and r = 0.910 (Pearson) and r = 0.883 (Spearman).
Page 17: cTn in Renal Failure
Elevated troponin levels in patients with renal failure, as noted in asymptomatic patients:
50% show increased troponin levels. Troponin I elevated in 7% and Troponin T in 17-53% of various renal failure stages, indicating differing release mechanisms due to tissue storage dynamics.
Mechanistic Insights: Troponin pathways suggest potential markers indicative of silent cardiac events and hypertrophy due to increased circulatory strain in renal conditions.
Page 18: Troponin Dynamics in Reperfusion
Observation of troponin concentrations during early/late reperfusion events against timing of occlusions.
Stratifications reveal distinct patterns reflective of the physiological responses of cardiac tissue during recovery and restoration of blood flow.
Page 19: Pathological cTn Elevations
Enumeration of conditions causing troponin elevation, documented in various pathological states including:
Extremities like extracorporeal vascular operations, sepsis, acute tocolysis, and multiorgan failure.
Each condition shows specific variability in tropinin elevations, emphasizing different clinical presentations linked to heart stress.
Page 20: Cardiac Troponins Overview
Highlights cardiospecificity and diagnostic strengths of cardiac troponins, their concentration elevation's direct connection to myocardial necrosis, long-term elevation patterns reflecting disease progression, and their predictive capacity for ongoing medical therapies.
Page 21: Limitations of Cardiac Troponins
The disadvantages include delayed elevation post-ischemia onset (typically 3 hours), variability in test methodology leading to inconsistent results, reliance on population-based reference values, and interindividual biological variability affecting troponin representation.
Page 22: Dynamic Changes Post-Ischemia
Examines the concentration timeline of serum biomarkers (myoglobin, CK-MB, troponin I) during the days following acute coronary ischemia, detailed in a temporal graph.
Page 23: Exercise Impact on Cardiac Troponins
studied dynamic troponin changes during strenuous exercise activities, showcasing the physiological stress impacts on cTn release patterns post-physical exertion or myocardial infarction scenarios.
Page 24: cTn Assay Patterns Post-Marathon
Empirical data on hsTnT concentrations recorded following marathon events indicate a pronounced surge, denoting clear differentiation in outcomes between various cardiovascular stress conditions like acute myocardial infarctions, non-ST elevated myocardial injuries, and myocarditis assessments in the post-exercise phase.
Page 25: Summary of Exercise-Induced cTn Changes
Graphical representation of post-exercise cTn levels across a participant population, illustrating various ranges of significance concerning cut-off levels indicative of heart distress.
Page 26: Novel Biomarkers
Introduction of microRNAs (miRNA) as emerging diagnostic tools, specifically highlighting:
miR-1, miR-133: Associated with cardiac hypertrophy and failure.
miR-499, miR-208: Highlighted in injury and fibrosis mechanisms.
Focus on miRNAs involved in specific cardiac conditions including infarction and endothelial modulation highlighted as potential therapeutic targets and diagnosis aids.
Page 27: Impact of miRNA in Cardiovascular Disease
Further elucidation of miRNAs linked to cardiovascular conditions, providing a comprehensive listing tied to various states from normal heart physiology to failure, dilated cardiomyopathy, and further validated studies on their predictive abilities.
Page 28: miRNA Mechanisms of Action
Details the biochemical action of miRNAs, including transcription mechanisms, mRNA inhibition, and degradation pathways, impacting protein synthesis via multisignal transduction pathways leading to cellular alterations under stress conditions.
Page 29: Pathological Circumstances Affecting miRNA Expression
Overview of how pathological stressors trigger miRNA expression in cardiac injury contexts, leading to regulatory shifts influencing downstream gene expressions critical for heart cell functionalities.
Page 30: miRNA as Early Diagnostic Markers in Diabetic Heart Disease
Illustrates the potential of assessing cardiac-specific miRNA alterations in diagnosing early diabetic heart conditions, advocating for advanced collection and testing strategies to catch the disease early and initiate preventive measures.
Page 31: Current Studies and New Biomarkers
Indicators of metabolic shifts within failing hearts, outlining various biochemical pathways and substrates (fatty acids, glucose levels, amino acids) as novel biomarkers reflecting heart disease status, integrating laboratory results with ongoing research to validate emerging diagnostics.
Page 32: VTLi Clinical Measurements
Summary of relevant clinical measurement ranges and specifications, significant metrics concerning hs-cTn detection capabilities indicating effectiveness in acute settings.
Page 33: Strategy for Testing
Guidance for the use of laboratory tests in the context of suspected acute ischemia, emphasizing repeat testing protocols to mitigate false positives and confirm myocardial impairment safely.
Page 34: cTn Measurement Recommendations
Advises on timing and frequency of cTn tests for accurate clinical interpretation, focusing on relative change significance, where a 20% change is deemed clinically relevant.
Page 35: ESC Guidelines Summary
Follow the European Society of Cardiology guidelines for managing acute coronary syndromes without persistent ST-segment elevation, emphasizing simultaneous evaluation of clinical settings, ECG findings, and troponin levels.
Page 36: Risk Stratification Techniques in Early AIM
Evaluation framework for suspected ACS cases without ST-segment elevation, integrating hs-cTn levels to prioritize clinical pathways for patient management and risk assessment nuances.
Page 37: Supplementary Examinations for Cardiovascular Disease
Key diagnostic measures include blood counts for anemia screening, electrolyte levels, renal function tests, glucose metrics, and echocardiography in determining heart failure causes.
Page 38: Summary of Investigated Parameters for ACS Diagnosis
Comprehensive table summarizing biomarkers currently utilized for diagnosing acute coronary syndrome (ACS), differentiating cardiac conditions from lung diseases, and outlining tests being phased out or emerging as experimental.
Page 39: Natriuretic Peptides Overview
Discussion on natriuretic peptides as intrinsic vasodilators alongside their biochemical actions affecting cardiovascular regulation, providing a framework for therapeutic exploration in heart disease treatment.
Page 40: Functionality of Natriuretic Peptides
Overview of the functional biological roles of natriuretic peptides, emphasizing their physiological benefits in regulating blood volume and systemic vascular resistance.
Page 41: Natriuretic Peptides as Vasodilators
Detailed mechanisms of action illustrating the vasoactive properties of natriuretic peptides, including implications on fluid retention and interaction with renin-aldosterone mechanisms influencing cardiac load.
Page 42: Discerning Cardiac vs Non-Cardiac Dyspnea
A pivotal reference discussing approaches comparing the influences of BNP against pulmonary complications, aiding intensivists and pulmonologists in rapidly diagnosing and treating heart failure.
Page 43: Heart Failure Diagnostic Protocols
General protocol outlining diagnostic puzzles in suspected heart failure cases, stressing educational points for interpreting ECG and NT-proBNP levels for accurate conditions assessments.
Page 44: Laboratory Diagnosis of Pulmonary Embolism
Explores laboratory methods for identifying pulmonary embolism inclusive of D-dimer testing and biomarkers correlation with incidence data segmented by demographic features.
Page 45: References
Literature referenced including various foundational texts and recent studies to provide context and further reading for understanding laboratory diagnostics in cardiac ischemia.